Presented by Biovays…

• The biggest news of the day was Genzyme and Isis’ Mipomersen, an antisense therapeutic that inhibits ApoB lipoprotein in patients with homozygous familial hypercholesterolemia. The drug showed a 25% reduction in LDL vs. 3% in patients on placebo. Shares of Isis dropped about 10% on concerns of liver toxicity, delayed registration and potential limited use in a chronic setting in patients with less severe disease. [The Motley Fool]

• Just as we all figured based on the medical reviewer’s briefing documents, the FDA Gastrointestinal Advisory Committee rejected Salix’s and Debiopharm’s Sanvar for esophageal bleeding 14-0. [Reuters]

• Array BioPharma is getting $40M in funding from Deerfield Management. [Forbes]

• Cephalon finally gets a controlling interest in Australia’s Arana Therapeutics — 50.1%. [Bio-Medicine]

• The NIH says its committing $24M per year to developing drugs for neglected diseases. [WSJ Health Blog]

• The state of Vermont is now requiring all drug and device companies to publicly disclose all payments to doctors and other healthcare providers. Crap, it’s time to practice in N.H. [FiercePharma]

• Finally, take a look at this video and check out the CEO’s of Genzyme, Charles River Laboratories, Vertex Pharmaceuticals and Millipore give their spiel on the economy and who they think will visit The Graveyard…

Anonymous Tip? Comments? Contact us at: hr@iguanabio.com

Image from isispharm

Related Posts